# Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice

> **NCT07663786** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 726 (estimated)

## Conditions studied

- Esophageal Adenocarcinoma
- Gastro-esophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07663786
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-09
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 726 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663786, "Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07663786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*